The AIDS Drug Assistance Programs (ADAP) Advocacy has released a critical policy paper examining potential systemic vulnerabilities in the 340B Drug Pricing Program, the nation's second-largest federally sponsored drug program. The report, titled "Is the 340B Drug Pricing Program the Next 'Too Big to Fail'?", suggests significant governance and accountability concerns that could compromise the program's effectiveness.
ADAP Advocacy leadership argues that the Health Resources Service Administration (HRSA) has failed to provide adequate oversight, similar to how the Securities & Exchange Commission overlooked critical issues before the 2008 financial crisis. The organization highlights several key concerns, including duplicative Medicaid discounts, drug diversion through contract pharmacies, and insufficient transparency standards.
The policy paper raises critical questions about the program's current trajectory, particularly focusing on how large hospital systems are benefiting from the program's growth. Advocates point to declining charity care levels and increasing medical debt as indicators of potential systemic problems that require immediate attention.
Marcus J. Hopkins, ADAP Advocacy's 340B Consultant, emphasized the stakes, noting that patients' lives depend on the program's success. The report suggests that without meaningful reforms, the 340B Drug Pricing Program risks becoming unsustainable and potentially failing to serve its intended purpose of supporting vulnerable patient populations.
Guy Anthony, Chair of the 340B Patient Advisory Committee, drew a direct comparison to the 2008 financial crisis, arguing that bold, decisive action is necessary to prevent potential systemic failure. The organization advocates for enhanced accountability and transparency to ensure the program's long-term viability and effectiveness.
